April’s eNews is here to continue the #lifesciences conversation on:
✅ Upcoming Events
✅ Storytelling in Corporate Communication
✅ Our Collaboration with United Airlines
✅ Meet our Ecosystem in our Annual Review
✅ ON Helix
✅ Cambridge Facilities and Lab Space
Read it here
News
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER
- Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A
- Will play a key role in building and executing Arecor’s ambitious commercialisation and growth plans as pipeline of proprietary and partnered products advances
Arecor Therapeutics plc
(“Arecor” or the “Group”)
FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE
Download the latest Biocair Research: Discovering "a new normal" for Contract Research Organizations
Contract Research Organizations (CROs) have become vital partners in the drug development process, enabling biotech and pharmaceutical companies to develop and market life-saving drugs. To further understand the supply chain complexities for CROs, Biocair recently conducted a qualitative research study with CRO supply chain professionals.
Economic data shows uplifting effect on employment across both Knowledge Intensive (KI) and non-KI sectors in the Cambridgeshire and Peterborough region.
NRG Therapeutics Announces International Scientific Advisory Board
Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders.
In a fiercely competitive recruitment market, how do you make your company irresistible to the best tech talent?
Pharmaron announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM.
This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity.
Agility Life Sciences, an award-winning formulation development CDMO based in Nottingham, UK, and Solitek, experts in solid state development services for the pharmaceutical, agrochemical and fine chemical industries based in Barcelona, Spain, have entered into a Strategic Partnership agreement in order to accelerate the pharmaceutical development milestones of their clients.
As the tide recedes from the recent Spring Budget 2023, we explore what has changed regarding R&D tax incentives and how this may impact the UK’s life sciences and biotech industry.
WHAT IS THE BACKGROUND?
Before going into detail on the research and development (R&D) tax relief changes announced, it is helpful to recap the background.
There are currently two schemes of relief: